HIF1A and cancer: CRLX101 [161], a nanoparticle-drug conjugate, delivers camptothecin to cancer cells, sustaining HIF-1α inhibition and showing synergistic effects with anti-angiogenesis drugs like bevacizumab in rectal cancer models.